



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No. AM100081 01)

In re Application of:	)	Appln. No.: 09/659,643
	)	Confirmation No.: 6975
JAMES J. GIBBONS JR. <i>et al.</i>	)	Customer No.: 25291
	)	Group Art Unit: 1614
Filed: 09/12/2000	)	Examiner: Dwayne C. Jones
	)	
For: METHOD OF POTENTIATING	)	
CHEMOTHERAPY AND TREATING	)	Paper No.: 11
SOLID TUMORS	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT

Dear Sir:

Responsive to the Office communication mailed August 19, 2003, please amend the above-referenced patent application pursuant to the following instructions and consider the remarks in a favorable light.

INTRODUCTORY COMMENTS

In accordance with the revised amendment format under the requirements of 37 C.F.R. § 1.121, the amendment to the claims and a complete listing of all claims in the application begin on a separate sheet to facilitate separate indexing and electronic scanning of each part of the amendment document for placement in an e-file wrapper. As required, only the claim number and status indicate any cancelled or withdrawn claim. Due to the length of the text of all pending claims, the amendment is placed in the below Appendix and incorporated herein by reference. Kindly amend the claims as highlighted therein.

The amendment removes the nonelected subject matter from the claims and improves the readability of the claims to expedite prosecution towards an early allowance. In addition, the duplicate recitation of carboxy as a substituent of R<sub>2</sub>, R<sub>b</sub> and/or R<sub>c</sub> in Claim 4, the redundancy of listing both Adriamycin (trade name of doxorubicin) and doxorubicin (generic name of Adriamycin) in Claim 6 and other minor, obvious typographical or clerical errors in the claims have been appropriately corrected.